ALX Oncology CEO sells shares for tax obligations

ALX Oncology Holdings director and chief executive officer Jason Lettmann reported an open-market sale of 12,311 shares of common stock at $2.17 per share on March 19, 2026.

Rhea-AI Filing Summary

ALX Oncology Holdings director and chief executive officer Jason Lettmann reported an open-market sale of 12,311 shares of common stock at $2.17 per share on March 19, 2026. According to the filing, the shares were sold to satisfy his tax obligations related to the vesting of performance-based restricted stock units. After this transaction, he directly holds 293,609 shares of ALX Oncology common stock.

Insider Trade Summary

Net Seller: 12,311 shares

Net Sell 1 txn

Insider Lettmann Jason

Role CHIEF EXECUTIVE OFFICER

Sold 12,311 shs ($27K)

Type	Security	Shares	Price	Value
Sale	Common Stock	12,311	$2.17	$27K

Holdings After Transaction: Common Stock — 293,609 shares (Direct)

Footnotes (1)

1. F1. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of perfomance-based restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ALX Oncology (ALXO) CEO Jason Lettmann report in this Form 4 filing?

Jason Lettmann reported selling 12,311 shares of ALX Oncology common stock at $2.17 per share. The sale was disclosed as part of a Form 4 insider transaction report filed with regulators.

Why did ALX Oncology (ALXO) CEO Jason Lettmann sell 12,311 shares?

The shares were sold to satisfy tax obligations tied to the vesting of performance-based restricted stock units. This indicates the sale was made primarily for tax withholding needs rather than a discretionary portfolio change.

How many ALX Oncology (ALXO) shares does Jason Lettmann hold after the reported sale?

After the transaction, Jason Lettmann directly holds 293,609 shares of ALX Oncology common stock. This figure reflects his position immediately following the sale of 12,311 shares reported in the Form 4.

What was the sale price for the ALX Oncology (ALXO) shares in this Form 4?

The reported sale price was $2.17 per share for the 12,311 shares of ALX Oncology common stock. This price applies to the open-market sale disclosed for tax obligation purposes.

Was the ALX Oncology (ALXO) Form 4 transaction a market trade or related to compensation?

The transaction is coded as an open-market sale but is tied to vesting of performance-based restricted stock units. The filing specifies the sale was conducted to cover the reporting person’s related tax obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/23/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lettmann Jason

(Last) (First) (Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/19/2026		S(1)		12,311	D	$2.17	293,609	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of perfomance-based restricted stock units.

	/s/ Shelly Pinto, by power of attorney	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)